Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Golidocitinib combination therapy as first-line treatment in PTCL: Retrospective data from a single centre

View Full Paper
Ask AI
Bookmark
Share

Authors

LHLing Huang

Discussion

Loading...

Member takes

Overview

Retrospective data reveals high anti-tumor activity in newly diagnosed PTCL with combination therapy, indicating a viable first-line option.

Key Points

  • To evaluate the efficacy and safety of golidocitinib combined with CHOP-like chemotherapy as first-line treatment for PTCL.
  • 16 adult patients with PTCL treated with golidocitinib and CHOP-like chemotherapy regimen
  • Retrospective data collected from a single centre
  • Evaluation of patient demographics and clinical characteristics
  • 92.9% overall response rate observed in 14 evaluable patients
  • 42.9% complete response rate during the mid-term evaluation
  • 43.8% of patients experienced treatment-related adverse events, primarily neutropenia and pulmonary infection

Cite This Study

Ling Huang (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d548https://doi.org/10.1182/blood-2025-6305
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial2025 · 1 citations
  2. 2Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib2025
  3. 3Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)2026 · 2 citations
  4. 4Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis2025
  5. 5Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia2025